Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs

This publication has 53 references indexed in Scilit:

• First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography
  Clinical Cancer Research, 2004
• Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
  2004
• Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
  Journal of Clinical Oncology, 2004
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
  Journal of Clinical Oncology, 2003
• Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development
  European Journal of Clinical Pharmacology, 2003
• Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
  2003
• Metabolic activation of temozolomide measured in vivo using positron emission tomography.
  2003
• Pharmacokinetics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
  Current Pharmaceutical Design, 2003
• Noninvasive imaging of protein–protein interactions in living subjects by using reporter protein complementation and reconstitution strategies
  Proceedings of the National Academy of Sciences, 2002
• Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
  European Journal Of Cancer, 2002